TOP CATEGORY: Chemicals & Materials | Life Sciences | Banking & Finance | ICT Media

  1. Home
  2. purchase Customization

purchase customization

Leave This Empty:

choose chapter to purchase


Back to Report

table of content

Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Selective Cox-2 Inhibitors
1.2 Key Market Segments
1.2.1 Selective Cox-2 Inhibitors Segment by Type
1.2.2 Selective Cox-2 Inhibitors Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Selective Cox-2 Inhibitors Market Overview
2.1 Global Market Overview
2.1.1 Global Selective Cox-2 Inhibitors Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Selective Cox-2 Inhibitors Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Selective Cox-2 Inhibitors Market Competitive Landscape
3.1 Global Selective Cox-2 Inhibitors Sales by Manufacturers (2019-2024)
3.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Manufacturers (2019-2024)
3.3 Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Selective Cox-2 Inhibitors Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Selective Cox-2 Inhibitors Sales Sites, Area Served, Product Type
3.6 Selective Cox-2 Inhibitors Market Competitive Situation and Trends
3.6.1 Selective Cox-2 Inhibitors Market Concentration Rate
3.6.2 Global 5 and 10 Largest Selective Cox-2 Inhibitors Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Selective Cox-2 Inhibitors Industry Chain Analysis
4.1 Selective Cox-2 Inhibitors Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Selective Cox-2 Inhibitors Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Selective Cox-2 Inhibitors Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Selective Cox-2 Inhibitors Sales Market Share by Type (2019-2024)
6.3 Global Selective Cox-2 Inhibitors Market Size Market Share by Type (2019-2024)
6.4 Global Selective Cox-2 Inhibitors Price by Type (2019-2024)
7 Selective Cox-2 Inhibitors Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Selective Cox-2 Inhibitors Market Sales by Application (2019-2024)
7.3 Global Selective Cox-2 Inhibitors Market Size (M USD) by Application (2019-2024)
7.4 Global Selective Cox-2 Inhibitors Sales Growth Rate by Application (2019-2024)
8 Selective Cox-2 Inhibitors Market Segmentation by Region
8.1 Global Selective Cox-2 Inhibitors Sales by Region
8.1.1 Global Selective Cox-2 Inhibitors Sales by Region
8.1.2 Global Selective Cox-2 Inhibitors Sales Market Share by Region
8.2 North America
8.2.1 North America Selective Cox-2 Inhibitors Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Selective Cox-2 Inhibitors Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Selective Cox-2 Inhibitors Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Selective Cox-2 Inhibitors Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Selective Cox-2 Inhibitors Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Boehringer-Ingelheim
9.1.1 Boehringer-Ingelheim Selective Cox-2 Inhibitors Basic Information
9.1.2 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Overview
9.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Product Market Performance
9.1.4 Boehringer-Ingelheim Business Overview
9.1.5 Boehringer-Ingelheim Selective Cox-2 Inhibitors SWOT Analysis
9.1.6 Boehringer-Ingelheim Recent Developments
9.2 TerSera Therapeutics
9.2.1 TerSera Therapeutics Selective Cox-2 Inhibitors Basic Information
9.2.2 TerSera Therapeutics Selective Cox-2 Inhibitors Product Overview
9.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Product Market Performance
9.2.4 TerSera Therapeutics Business Overview
9.2.5 TerSera Therapeutics Selective Cox-2 Inhibitors SWOT Analysis
9.2.6 TerSera Therapeutics Recent Developments
9.3 Iroko Pharmaceuticals
9.3.1 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.3.2 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.3.4 Iroko Pharmaceuticals Selective Cox-2 Inhibitors SWOT Analysis
9.3.5 Iroko Pharmaceuticals Business Overview
9.3.6 Iroko Pharmaceuticals Recent Developments
9.4 Apotex
9.4.1 Apotex Selective Cox-2 Inhibitors Basic Information
9.4.2 Apotex Selective Cox-2 Inhibitors Product Overview
9.4.3 Apotex Selective Cox-2 Inhibitors Product Market Performance
9.4.4 Apotex Business Overview
9.4.5 Apotex Recent Developments
9.5 Yung Shin Pharmaceutical
9.5.1 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.5.2 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.5.4 Yung Shin Pharmaceutical Business Overview
9.5.5 Yung Shin Pharmaceutical Recent Developments
9.6 Breckenridge Pharmaceutical
9.6.1 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.6.2 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.6.4 Breckenridge Pharmaceutical Business Overview
9.6.5 Breckenridge Pharmaceutical Recent Developments
9.7 Meda Pharmaceuticals
9.7.1 Meda Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.7.2 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.7.4 Meda Pharmaceuticals Business Overview
9.7.5 Meda Pharmaceuticals Recent Developments
9.8 Cipla
9.8.1 Cipla Selective Cox-2 Inhibitors Basic Information
9.8.2 Cipla Selective Cox-2 Inhibitors Product Overview
9.8.3 Cipla Selective Cox-2 Inhibitors Product Market Performance
9.8.4 Cipla Business Overview
9.8.5 Cipla Recent Developments
9.9 Glenmark Pharmaceuticals
9.9.1 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.9.2 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.9.4 Glenmark Pharmaceuticals Business Overview
9.9.5 Glenmark Pharmaceuticals Recent Developments
9.10 Teva
9.10.1 Teva Selective Cox-2 Inhibitors Basic Information
9.10.2 Teva Selective Cox-2 Inhibitors Product Overview
9.10.3 Teva Selective Cox-2 Inhibitors Product Market Performance
9.10.4 Teva Business Overview
9.10.5 Teva Recent Developments
9.11 PuraCap Pharmaceutical
9.11.1 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.11.2 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.11.4 PuraCap Pharmaceutical Business Overview
9.11.5 PuraCap Pharmaceutical Recent Developments
9.12 Almirall Limited
9.12.1 Almirall Limited Selective Cox-2 Inhibitors Basic Information
9.12.2 Almirall Limited Selective Cox-2 Inhibitors Product Overview
9.12.3 Almirall Limited Selective Cox-2 Inhibitors Product Market Performance
9.12.4 Almirall Limited Business Overview
9.12.5 Almirall Limited Recent Developments
9.13 Lupin Pharmaceuticals
9.13.1 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.13.2 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.13.4 Lupin Pharmaceuticals Business Overview
9.13.5 Lupin Pharmaceuticals Recent Developments
9.14 Aurobindo Pharma
9.14.1 Aurobindo Pharma Selective Cox-2 Inhibitors Basic Information
9.14.2 Aurobindo Pharma Selective Cox-2 Inhibitors Product Overview
9.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Product Market Performance
9.14.4 Aurobindo Pharma Business Overview
9.14.5 Aurobindo Pharma Recent Developments
9.15 Pfizer
9.15.1 Pfizer Selective Cox-2 Inhibitors Basic Information
9.15.2 Pfizer Selective Cox-2 Inhibitors Product Overview
9.15.3 Pfizer Selective Cox-2 Inhibitors Product Market Performance
9.15.4 Pfizer Business Overview
9.15.5 Pfizer Recent Developments
9.16 Mylan
9.16.1 Mylan Selective Cox-2 Inhibitors Basic Information
9.16.2 Mylan Selective Cox-2 Inhibitors Product Overview
9.16.3 Mylan Selective Cox-2 Inhibitors Product Market Performance
9.16.4 Mylan Business Overview
9.16.5 Mylan Recent Developments
9.17 Takeda
9.17.1 Takeda Selective Cox-2 Inhibitors Basic Information
9.17.2 Takeda Selective Cox-2 Inhibitors Product Overview
9.17.3 Takeda Selective Cox-2 Inhibitors Product Market Performance
9.17.4 Takeda Business Overview
9.17.5 Takeda Recent Developments
9.18 Bayer
9.18.1 Bayer Selective Cox-2 Inhibitors Basic Information
9.18.2 Bayer Selective Cox-2 Inhibitors Product Overview
9.18.3 Bayer Selective Cox-2 Inhibitors Product Market Performance
9.18.4 Bayer Business Overview
9.18.5 Bayer Recent Developments
9.19 Novacap
9.19.1 Novacap Selective Cox-2 Inhibitors Basic Information
9.19.2 Novacap Selective Cox-2 Inhibitors Product Overview
9.19.3 Novacap Selective Cox-2 Inhibitors Product Market Performance
9.19.4 Novacap Business Overview
9.19.5 Novacap Recent Developments
9.20 Abbott
9.20.1 Abbott Selective Cox-2 Inhibitors Basic Information
9.20.2 Abbott Selective Cox-2 Inhibitors Product Overview
9.20.3 Abbott Selective Cox-2 Inhibitors Product Market Performance
9.20.4 Abbott Business Overview
9.20.5 Abbott Recent Developments
9.21 Geri-Care
9.21.1 Geri-Care Selective Cox-2 Inhibitors Basic Information
9.21.2 Geri-Care Selective Cox-2 Inhibitors Product Overview
9.21.3 Geri-Care Selective Cox-2 Inhibitors Product Market Performance
9.21.4 Geri-Care Business Overview
9.21.5 Geri-Care Recent Developments
9.22 Perrigo
9.22.1 Perrigo Selective Cox-2 Inhibitors Basic Information
9.22.2 Perrigo Selective Cox-2 Inhibitors Product Overview
9.22.3 Perrigo Selective Cox-2 Inhibitors Product Market Performance
9.22.4 Perrigo Business Overview
9.22.5 Perrigo Recent Developments
9.23 Kopran
9.23.1 Kopran Selective Cox-2 Inhibitors Basic Information
9.23.2 Kopran Selective Cox-2 Inhibitors Product Overview
9.23.3 Kopran Selective Cox-2 Inhibitors Product Market Performance
9.23.4 Kopran Business Overview
9.23.5 Kopran Recent Developments
9.24 Merck
9.24.1 Merck Selective Cox-2 Inhibitors Basic Information
9.24.2 Merck Selective Cox-2 Inhibitors Product Overview
9.24.3 Merck Selective Cox-2 Inhibitors Product Market Performance
9.24.4 Merck Business Overview
9.24.5 Merck Recent Developments
9.25 Hengrui pharmaceutical
9.25.1 Hengrui pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.25.2 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.25.4 Hengrui pharmaceutical Business Overview
9.25.5 Hengrui pharmaceutical Recent Developments
9.26 Kelun Group
9.26.1 Kelun Group Selective Cox-2 Inhibitors Basic Information
9.26.2 Kelun Group Selective Cox-2 Inhibitors Product Overview
9.26.3 Kelun Group Selective Cox-2 Inhibitors Product Market Performance
9.26.4 Kelun Group Business Overview
9.26.5 Kelun Group Recent Developments
9.27 Qilu Pharmaceutical
9.27.1 Qilu Pharmaceutical Selective Cox-2 Inhibitors Basic Information
9.27.2 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Overview
9.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Product Market Performance
9.27.4 Qilu Pharmaceutical Business Overview
9.27.5 Qilu Pharmaceutical Recent Developments
9.28 Taro Pharmaceuticals
9.28.1 Taro Pharmaceuticals Selective Cox-2 Inhibitors Basic Information
9.28.2 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Overview
9.28.3 Taro Pharmaceuticals Selective Cox-2 Inhibitors Product Market Performance
9.28.4 Taro Pharmaceuticals Business Overview
9.28.5 Taro Pharmaceuticals Recent Developments
10 Selective Cox-2 Inhibitors Market Forecast by Region
10.1 Global Selective Cox-2 Inhibitors Market Size Forecast
10.2 Global Selective Cox-2 Inhibitors Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Selective Cox-2 Inhibitors Market Size Forecast by Country
10.2.3 Asia Pacific Selective Cox-2 Inhibitors Market Size Forecast by Region
10.2.4 South America Selective Cox-2 Inhibitors Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Selective Cox-2 Inhibitors by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Selective Cox-2 Inhibitors Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Selective Cox-2 Inhibitors by Type (2025-2030)
11.1.2 Global Selective Cox-2 Inhibitors Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Selective Cox-2 Inhibitors by Type (2025-2030)
11.2 Global Selective Cox-2 Inhibitors Market Forecast by Application (2025-2030)
11.2.1 Global Selective Cox-2 Inhibitors Sales (K Units) Forecast by Application
11.2.2 Global Selective Cox-2 Inhibitors Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings